MNOV catalyst calendar

MEDICINOVA INC

Upcoming catalysts
2
Cash runway
22 months
Cash & investments
$25M
Phase 3 programs
1

MEDICINOVA INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia on December 31, 2026. There are 2 upcoming events on record.

Cash runway is approximately 22 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 15 concluded trials, 93% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
December 31, 2026 MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia Trial Milestone Phase 2
April 15, 2027 Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS Trial Milestone Phase 2/Phase 3

Track MNOV alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open MNOV in the tracker

Recent history

DateEventTypePhase
September 28, 2026 8-K filed: Material agreement Corporate —
August 19, 2026 8-K filed: Leadership change Corporate —
February 20, 2026 Quarterly results filed (8-K) Earnings —
December 30, 2025 8-K filed: Material agreement Corporate —
August 1, 2025 8-K filed: Material agreement Corporate —
August 7, 2023 Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma Trial Milestone Phase 1/Phase 2
June 30, 2022 Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS Trial Milestone Phase 2
December 7, 2020 Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis Trial Milestone Phase 2
December 31, 2019 A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS) Trial Milestone Phase 1/Phase 2
July 17, 2019 Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers Trial Milestone Phase 1
July 6, 2018 Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers Trial Milestone Phase 1
May 30, 2018 Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects Trial Milestone Phase 2
August 15, 2017 Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) Trial Milestone Phase 2
May 15, 2017 Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.